Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the
breast. The lump or mass is usually painless, hard & irregular but
it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple
discharge, nipple retraction and presence of breast skin changes (eg
peau d' orange, nipple excoriation, scaling, inflammation, skin
tethering, ulceration, abscess).
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.
A structured cardiovascular (CV) exercise programme during adjuvant breast cancer treatment provides significant protection against decline in CV function related to chemotherapy-induced cardiotoxicity, according to the EBBA*-II trial presented at SABCS 2018, indicating that physical activity during treatment for breast cancer can benefit patients.
Treatment with the PD-L1 inhibitor atezolizumab on top of standard chemotherapy with nab-paclitaxel significantly improves progression-free survival (PFS) in triple-negative breast cancer (TNBC) compared with nab-paclitaxel alone, top-line results from the IMpassion* 130 trial reveal. In particular, median overall survival (OS) was 10 months longer with atezolizumab among PD-L1-positive (PD-L1+) patients in an interim analysis.
New drug applications approved by US FDA as of 16 - 31 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Adding the combination therapy of zoledronic acid + letrozole to triptorelin as adjuvant treatment for hormone receptor positive (HR+) early breast cancer in premenopausal women significantly improves disease-free survival (DFS) compared with the combination of tamoxifen and triptorelin, according to the HOBOE-2* study presented at ESMO 2018.
Levels of anti-Müllerian hormone (AMH) may not correlate with ovarian reserve in patients with breast cancer, suggests a study presented at ESHRE 2018, thus raising questions on the utility of AMH testing before hormonal stimulation in fertility preservation for women with breast cancer.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
Treatment with adjuvant trastuzumab for 6 months was noninferior to 12 months — the current standard treatment duration for HER2-positive early-stage breast cancer — in terms of disease-free survival (DFS), according to the PERSEPHONE* trial presented in ASCO 2018.
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.